Brief: MaxCyte Says Nasdaq Listing Unaffected By AIM Delisting - SEC Filing
25/06/2025 22:37
June 25 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE INC: HAD APPLIED TO LSE TO CANCEL ITS ADMISSION OF CO'S COMMON STOCK TO TRADING ON AIM MARKET OF LSE MAXCYTE INC - NASDAQ LISTING UNAFFECTED BY AIM DELISTING - SEC FILING Source text: [ID:n0001558370-25-008856] Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview